Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ELEKTA B

EKTAb.STSE0000163628NASDAQ StockholmSESEK
Stock price
ELEKTA B
Loading chart...

Coverage

Latest articles

Elekta outlines growth strategy, revises order backlog
11 Jun 2025, 19:27EKTAb.STNASDAQ Stockholm

Elekta AB detailed its future growth prospects and the results of a proactive order review at its Investor Update in Stockholm, the company said Tuesday.

Elekta revises order backlog down by 4.9 billion Swedish krona, targets 14% EBIT margin
10 Jun 2025, 09:03EKTAb.STNASDAQ Stockholm

Elekta announced a significant adjustment to its order backlog, cancelling orders valued at 4.9 billion Swedish Krona following a proactive review aimed at improving profitability and predictability.

Elekta names Jakob Just-Bomholt as new President and CEO
9 Jun 2025, 20:29EKTAb.STNASDAQ Stockholm

Elekta has appointed Jakob Just-Bomholt as its new President and CEO, effective September 1, 2025, the medical technology firm announced.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 20:26EKTAb.STNASDAQ Stockholm

Elekta announced Monday the appointment of Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 17:06EKTAb.STNASDAQ Stockholm

Elekta has named Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025, the company announced.

Elekta reports mixed full-year results amid R&D impairment
8 Jun 2025, 20:30EKTAb.STNASDAQ Stockholm

Swedish medical technology firm Elekta reported a net loss of 381 million Swedish Kronor for its fourth quarter, impacted by a 1.064 billion Swedish Kronor non-cash impairment from discontinued research and development projects, the company said.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
ELEKTA RECEIVES FDA 510 (k) CLEARANCE FOR MONACO VMAT TREATMENT PLANNING SOLUTION24 Jul 2009
C-RAD SENTINEL™ SELECTED AS ELEKTA PREFERRED SOLUTION FOR INTRA FRACTION MOTION DETECTION21 Jul 2009
ELEKTA AND SWEDFUND INVEST IN CANCER CARE IN DEVELOPING COUNTRIES1 Jul 2009
ELEKTA PROVIDES VMAT AND RADIOSURGERY SOLUTIONS FOR NEW JERSEY HEALTH SYSTEM18 Jun 2009
ELEKTA SIGNS COOPERATIVE AGREEMENT WITH SWEDISH EXPORT CREDIT CORPORATION15 Jun 2009
Year-end report May - April 2008/0910 Jun 2009
ELEKTA AND THE OTTAWA HOSPITAL FORGE LONG-TERM STRATEGIC PARTNERSHIP AGREEMENT27 May 2009
REMINDER: INVITATION TO ELEKTA'S CAPITAL MARKETS DAY27 May 2009
PROCURE TREATMENT CENTERS TO EQUIP CHICAGO FACILITY WITH SOFTWARE SOLUTIONS FROM ELEKTA26 May 2009
ELEKTA AND NUCLETRON COMBINE FORCES TO MARKET LEADING SOFTWARE18 May 2009
INVITATION: ELEKTA'S FULL YEAR REPORT AND CAPITAL MARKETS DAY14 May 2009
U.K. CANCER CENTRE BEGINS INNOVATIVE RADIOTHERAPY TREATMENT WITH FOUR ELEKTA SYSTEMS11 May 2009
  • Previous
  • 1
  • More pages
  • 45
Search
Company
ELEKTA B
EKTAb.STNASDAQ Stockholm
Website: Unavailable
Coverage
12
  • Next
  • 46
  • 47
  • More pages
  • 59
  • Next
  • Filings
    703